Cargando…

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iorio, Alfonso, Edginton, Andrea N., Blanchette, Victor, Blatny, Jan, Boban, Ana, Cnossen, Marjon, Collins, Peter, Croteau, Stacy E., Fischer, Katheljin, Hart, Daniel P., Ito, Shinya, Korth‐Bradley, Joan, Lethagen, Stefan, Lillicrap, David, Makris, Mike, Mathôt, Ron, Morfini, Massimo, Neufeld, Ellis J., Spears, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Online‐only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046594/ https://www.ncbi.nlm.nih.gov/pubmed/30046759 http://dx.doi.org/10.1002/rth2.12106

Ejemplares similares

Focusing in on use of pharmacokinetic profiles in routine hemophilia care
por: Croteau, Stacy E., et al.
Publicado: (2018)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
por: Yu, Jacky K., et al.
Publicado: (2019)

A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
por: Blanchette, Victor S., et al.
Publicado: (2021)

PB2647: USE OF EMICIZUMAB FOR THE TREATMENT OF ACQUIRED HEMOPHILIA A: A SYSTEMATIC REVIEW
por: Al-Housni, Zainab, et al.
Publicado: (2023)

Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice
por: Goedhart, Tine M. H. J., et al.
Publicado: (2021)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation
por: Bukkems, Laura H., et al.
Publicado: (2023)

Relationship between factor VIII levels and bleeding for rFVIII‐SingleChain in severe hemophilia A: A repeated time‐to‐event analysis
por: Bukkems, Laura H., et al.
Publicado: (2023)

Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
por: Preijers, Tim, et al.
Publicado: (2020)

PB2323: ACQUIRED HEMOPHILIA: A CASE REPORT
por: Haddad, N., et al.
Publicado: (2022)

PB2329: ACQUIRED HEMOPHILIA-POTENTIALLY FATAL IF NOT TREATED PROMPTLY
por: Stankovikj, S., et al.
Publicado: (2022)

PB2649: THE SURGICAL OUTCOMES IN PEDIATRICS PATIENTS WITH HEMOPHILIA, THE ROYAL HOSPITAL EXPERIENCE, OMAN
por: Al Hajri, Alia, et al.
Publicado: (2023)

PB2518: OPTIMIZING THE DETECTION OF 2,3- DIPHOSPHOGLYCERATE IN DRIED BLOOD SPOTS OF PATIENTS WITH SICKLE CELL DISEASE: UNTARGETED METABOLOMICS WITHIN THE GENOMED4ALL PROJECT
por: van der Veen, Sigrid, et al.
Publicado: (2023)

PB2654: RARE BLEEDING DISORDERS: LONG-TERM EXPERIENCE FROM A HEMOPHILIA CENTER
por: Meimaridis, Antonios, et al.
Publicado: (2023)

PB2643: EFFICACY OF REDUCED-DOSE EMICIZUMAB IN HEMOPHILIA A WITH INHIBITORS: REAL WORLD EXPERIENCE IN MALAYSIA
por: Tang, Andy Sing Ong, et al.
Publicado: (2023)

PB2064: THE COMPLETE STUDY: A SINGLE ARM, MULTICENTER OBSERVATIONAL STUDY TO EVALUATE EFFECTIVENESS OF PEGCETACOPLAN UNDER REAL WORLD CONDITIONS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
por: de Latour, Régis Peffault, et al.
Publicado: (2023)

PB2648: THE RELATIONSHIP BETWEEN BALANCE CONFIDENCE, KINESIOPHOBIA AND LEG MUSCLE STRENGTH AMONG ADULT HEMOPHILIA PATIENTS
por: Aykar, Sercan Onal, et al.
Publicado: (2023)

Future prospects for the treatment of hemophilia: A global perspective
por: Lillicrap, David
Publicado: (2018)

Pharmacokinetic‐tailored approach to hemophilia prophylaxis: Medical decision making and outcomes
por: Croteau, Stacy E., et al.
Publicado: (2020)

Recent Advances in the Treatment of Hemophilia: A Review
por: Marchesini, Emanuela, et al.
Publicado: (2021)

PB2674: CLINICAL, NEUROIMAGING, AND BEHAVIORAL RISK FACTORS FOR NEUROCOGNITIVE IMPAIRMENT IN CHINESE PATIENTS WITH HEMOPHILIA: A MULTICENTER STUDY
por: Cheung, Yin Ting, et al.
Publicado: (2023)

Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

Antithrombin lowering in hemophilia: a closer look at fitusiran
por: Young, Guy, et al.
Publicado: (2023)

PB2325: APPLICATION AND COMPARISON OF TWO PHARMACOKINETIC DETECTION METHODS IN CHILDREN WITH HEMOPHILIA A—AN INSPECTION REPORT FROM SINGLE CENTER
por: Li, C.-G., et al.
Publicado: (2022)

Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
por: Chelle, Pierre, et al.
Publicado: (2019)

Hemophilia Gene Therapy: Approaching the First Licensed Product
por: Batty, Paul, et al.
Publicado: (2021)

Considerations for shared decision management in previously untreated patients with hemophilia A or B
por: Astermark, Jan, et al.
Publicado: (2023)

Patient‐relevant health outcomes for hemophilia care: Development of an international standard outcomes set
por: van Balen, Erna C., et al.
Publicado: (2021)

PB2320: AN INDICTION OF TREATING ADULT HEMOPHILIA IN A DEVELOPING COUNTRY: A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE “PART I DESCRIPTIVE EPIDEMIOLOGY”
por: Elbogdady, M., et al.
Publicado: (2022)

Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patients
por: Preijers, Tim, et al.
Publicado: (2021)

Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo)
por: McEneny-King, Alanna, et al.
Publicado: (2016)

PB2231: RATIONALE FOR THE USE OF COMBINATION CHELATION THERAPY IN PATIENTS WITH THALASSEMIA SYNDROMES OR SICKLE CELL ANEMIA: A SYSTEMATIC LITERATURE REVIEW
por: Kattamis, A., et al.
Publicado: (2022)

Joint status of patients with nonsevere hemophilia A
por: Zwagemaker, Anne‐Fleur, et al.
Publicado: (2022)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates
por: Preijers, Tim, et al.
Publicado: (2021)

Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol
por: Iorio, Alfonso, et al.
Publicado: (2016)

High use of pain, depression, and anxiety drugs in hemophilia: more than 3000 people with hemophilia in an 11-year Nordic registry study
por: Steen Carlsson, Katarina, et al.
Publicado: (2023)

A second retrospective database analysis confirms prior findings of apparent increased cardiovascular comorbidities in hemophilia A in the United States
por: Humphries, Thomas J., et al.
Publicado: (2016)

PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)
por: Holstein, Sarah A., et al.
Publicado: (2023)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rtib6r7a7kl2cg0uluepui58kj